tocilizumab

Description

Tocilizumab (Actemra) – Targeted Therapy for Autoimmune and Inflammatory Conditions

Overview

Tocilizumab, marketed as Actemra, is a prescription monoclonal antibody used to treat autoimmune and inflammatory conditions. It works by inhibiting the interleukin-6 (IL-6) receptor, a protein that plays a key role in the immune response and inflammation. Tocilizumab is commonly prescribed for conditions such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome, offering targeted therapy to reduce inflammation and manage symptoms.

Key Features / Indications

• Active Ingredient: Tocilizumab
• Brand Name: Actemra
• Therapeutic Class: Monoclonal Antibody / IL-6 Receptor Inhibitor
• Indications:

o Moderate to severe rheumatoid arthritis (RA)

o Systemic juvenile idiopathic arthritis (sJIA)

o Giant cell arteritis (GCA)

o Cytokine release syndrome (CRS) associated with CAR-T cell therapy

• Administration: Intravenous infusion or subcutaneous injection, as prescribed
• Mechanism of Action: Blocks IL-6 receptors to reduce inflammation and immune system overactivity
• Benefits:

o Targeted therapy for autoimmune and inflammatory conditions

o Reduces joint inflammation, pain, and systemic symptoms

o Can be used alone or in combination with other therapies

o Flexible administration options for patient convenience

Why Choose Oncomed Pharmacy?

Oncomed Pharmacy provides authentic, high-quality Tocilizumab (Actemra) with professional storage, handling, and guidance on safe administration. Our pharmacists assist patients with dosing, monitoring for side effects, and ongoing care to ensure effective and safe therapy. Choosing Oncomed Pharmacy ensures reliable access to advanced biologic therapies with dedicated support throughout your treatment.

Uses of Medicine

Tocilizumab (Actemra) is primarily used for:

• Treating rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis (sJIA)
• Managing giant cell arteritis (GCA)
• Treating cytokine release syndrome (CRS) in CAR-T therapy patients
• Reducing inflammation and overactive immune responses
• Supporting combination therapy in autoimmune and inflammatory conditions